GLP-1 receptor agonists like tirzepatide ranked as the second most effective treatment for reducing sleep apnea severity, trailing only CPAP in this umbrella review of 230 clinical trials.
-21.86 events/hourTirzepatide (GLP-1 agonist) reduced sleep apnea breathing interruptions by nearly 22 events per hour, ranking second only to CPAP across 230 randomized trials
What the researchers found
In this umbrella review of 230 RCTs involving 36,353 participants, CPAP was the most effective treatment for reducing the apnea-hypopnea index (AHI), with a mean difference of -30.7 events/hour. GLP-1 receptor agonists ranked second: tirzepatide reduced AHI by 21.86 events/hour (SMD -0.84, 95% CI -1.01 to -0.68; moderate-certainty evidence). Mandibular advancement devices came third with an AHI reduction of 11.91 events/hour. For quality of life, physical activity showed the greatest improvement (SMD 1.3), while CPAP showed modest benefits. Only 3% of included evidence was high-certainty, with 68% moderate and 35% low.
Why it matters
This is one of the first comprehensive evidence reviews to directly compare GLP-1 receptor agonists against established sleep apnea treatments like CPAP. The finding that tirzepatide ranks second only to CPAP for reducing breathing interruptions is significant — it suggests that peptide-based weight loss medications could become a major treatment option for sleep apnea, potentially offering an alternative for patients who struggle with CPAP adherence.
How the study worked
The researchers conducted an umbrella review — a systematic review of meta-analyses — searching PubMed, Embase, Web of Science, and Cochrane from January 2017 to July 2025. They included meta-analyses of randomized controlled trials evaluating sleep apnea interventions. When multiple meta-analyses covered the same treatment-outcome pair, they retained the one with the most RCTs. Quality was assessed using AMSTAR 2, and evidence certainty was graded using the GRADE framework. The protocol was pre-registered in PROSPERO.
What this study cannot tell us
Only 3% of included evidence was high-certainty. The review was limited to meta-analyses in English, which may exclude relevant non-English literature. Data on long-term safety, adherence, and combination therapies were scarce. The quality of the umbrella review depends on the quality of the underlying meta-analyses, some of which had methodological limitations.
How to read the evidence
This umbrella review represents a high level of evidence synthesis, covering 230 randomized controlled trials and 36,353 participants. The GLP-1 agonist findings specifically were rated as moderate-certainty evidence using the GRADE framework, which is relatively strong for this field.
When this study was published
Published in 2025 with literature searched through July 2025, this review includes the most current evidence on sleep apnea treatments including recently studied GLP-1 receptor agonists.
The bigger picture
Sleep apnea affects hundreds of millions of people worldwide, and CPAP adherence remains a major challenge. The emergence of GLP-1 receptor agonists as effective treatments opens a new therapeutic avenue, particularly for patients with obesity-related sleep apnea. This review positions peptide-based therapies alongside traditional mechanical and surgical interventions, potentially reshaping how clinicians approach sleep apnea treatment.
Questions still open
- Could GLP-1 receptor agonists replace CPAP for certain sleep apnea patients, particularly those with obesity-driven disease?
- What is the long-term efficacy and safety of tirzepatide specifically for sleep apnea treatment?
- Would combining GLP-1 agonists with CPAP or other treatments produce additive benefits?
Common questions
Can GLP-1 drugs like tirzepatide treat sleep apnea?
Is CPAP still the best treatment for sleep apnea?
Read the original research
Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trials.
EClinicalMedicine, 89, 103529
Citation
Figard, Camille; Ben Messaoud, Raoua; Baillieul, Sébastien; Joyeux-Faure, Marie; Destors, Marie; Tamisier, Renaud; Khouri, Charles; Pépin, Jean-Louis. (2025). Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trials.. EClinicalMedicine, 89, 103529. https://doi.org/10.1016/j.eclinm.2025.103529